This padding only appears when menu bar covers the content below (browser width 1199px)
We test the safety of chemicals for use in our everyday lives
We use an alternative to animal models, C. elegans, to test chemicals for neurotoxicity, developmental neurotoxicity, and developmental and reproductive toxicity. Our innovative high-throughput platform provides cost effective and rapid testing.
Newormics is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of Health/National Institute of Mental Health (NIMH) for the continued development of the company’s in vivo imaging and screening technologies.
Newormics Announces Intent to Grant Utility Patent on the vivoChip by the European Patent Office
Newormics LLC, a developer of the first high-throughput, high-content screening platforms for use with in vivo small animal models, announced that the European Patent Office (EPO) intends to grant a patent covering the vivoChip® technology, the device design and use for C. elegans studies.